Karen Young

Seattle Genetics, Celltech In $30M Antibody Conjugate Deal

March 29, 2002

Celltech Group plc and Seattle Genetics Inc. entered into a multiyear research collaboration to use Seattle Genetics’ antibody-drug conjugate technology with Celltech’s antibody fragments, initially for immunological targets. (BioWorld Today)

Karo Bio, Bristol-Myers Drop Lead Compound For Obesity

March 28, 2002

By Karen Young

Karo Bio, Bristol-Myers Drop Lead Compound For Obesity

March 28, 2002

By Karen Young

Memory Raises $40M To Fund Drug Discovery, Development

March 26, 2002

By Karen Young

Memory Raises $40M To Fund Drug Discovery, Development

March 26, 2002

By Karen Young

Aphton Sells 1.2M Shares, Raises $12.6M For Trials, Operations

March 25, 2002

By Karen Young

Aphton Sells 1.2M Shares, Raises $12.6M For Trials, Operations

March 25, 2002

By Karen Young

Cell Genesys Drops Gene Therapy Collaboration With GPC Biotech

March 22, 2002

By Karen Young

Hemosol’s Stock Falls 29 Percent After Hemolink Denial In Canada

March 22, 2002

By Karen Young

Cell Genesys Drops Gene Therapy Collaboration With GPC Biotech

March 22, 2002

By Karen Young

Articles by Karen Young

Seattle Genetics, Celltech In $30M Antibody Conjugate Deal

Karo Bio, Bristol-Myers Drop Lead Compound For Obesity

Karo Bio, Bristol-Myers Drop Lead Compound For Obesity

Memory Raises $40M To Fund Drug Discovery, Development

Memory Raises $40M To Fund Drug Discovery, Development

Aphton Sells 1.2M Shares, Raises $12.6M For Trials, Operations

Aphton Sells 1.2M Shares, Raises $12.6M For Trials, Operations

Cell Genesys Drops Gene Therapy Collaboration With GPC Biotech

Hemosol’s Stock Falls 29 Percent After Hemolink Denial In Canada

Cell Genesys Drops Gene Therapy Collaboration With GPC Biotech

Today's news in brief

News in brief

Psychedelic space expanding on Trump’s EO

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

At AACR: Epigenetic fingerprints in metastases track tumor origin